ALX Oncology Holdings Inc.
ALXOHealthcare|Biotechnology|US
$1.16
+0.01 (+0.43%)
DCF Value
$0.13
Tangible Book / Share
$1.00
Cash / Share
$1.02
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07007559 ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer | Breast Cancer, Metastatic | P2 | Recruiting | 120 | Open-label | Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine |
| NCT05868226 PRE-ISPY Phase I/II Oncology Platform Program | HER2-positive Breast Cancer, Metastatic Cancer | P1P2 | Recruiting | 280 | Open-label | ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 |
| NCT04675333 Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | P2 | Active | 172 | RCT, Open-label | evorpacept, pembrolizumab, Cisplatin/Carboplatin; 5FU |
| NCT05467670 Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | Ovarian Cancer | P2 | Active | 16 | Open-label | Pembrolizumab, ALX148, Doxorubicin |
| NCT04675294 Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | P2 | Active | 189 | RCT, Open-label | evorpacept, pembrolizumab |
| NCT07085091 A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC | P1 | Recruiting | 170 | RCT, Open-label | ALX2004, ALX2004, ALX2004 |
| NCT05002127 A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | P2P3 | Completed | 127 | RCT, Double-blind | Evorpacept (ALX148), Trastuzumab, Ramucirumab, Paclitaxel |
| NCT05027139 A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer | HER2-expressing Cancers | P1P2 | Completed | 52 | Open-label | Zanidatamab, Evorpacept |
| NCT05167409 Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Microsatellite Stable Metastatic Colorectal Cancer | P2 | Terminated | 19 | Open-label | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
| NCT04417517 A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) | Higher Risk Myelodysplastic Syndromes | P1 | Terminated | 65 | RCT, Single-blind | evorpacept, azacitidine |
| NCT05524545 A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | Bladder Cancer, Urothelial Carcinoma | P1 | Completed | 36 | Open-label | Evorpacept, Enfortumab Vedotin |
| NCT03013218 A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | Metastatic Cancer, Solid Tumor | P1 | Completed | 174 | Open-label | Evorpacept (ALX148), Pembrolizumab, Trastuzumab, Rituximab, Ramucirumab + Paclitaxel, 5-FU + Cisplatin |
| NCT04755244 A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | Acute Myeloid Leukemia, AML, Adult | P1 | Terminated | 14 | Open-label | evorpacept, venetoclax, azacitidine |